Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

SQZ Biotechnologies Company (SQZ)

0.6041   -0.196 (-24.49%) 03-24 16:00
Open: 0.742 Pre. Close: 0.8
High: 0.7579 Low: 0.54
Volume: 1,960,942 Market Cap: 18(M)

Technical analysis

as of: 2023-03-24 4:30:08 PM
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 0.86     One year: 1.01
Support: Support1: 0.52    Support2: 0.44
Resistance: Resistance1: 0.74    Resistance2: 0.87
Pivot: 0.64
Moving Average: MA(5): 0.63     MA(20): 0.67
MA(100): 1.23     MA(250): 2.44
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 48.4     %D(3): 37.4
RSI: RSI(14): 44.4
52-week: High: 5.19  Low: 0.52
Average Vol(K): 3-Month: 330 (K)  10-Days: 1,350 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ SQZ ] has closed above bottom band by 39.1%. Bollinger Bands are 34.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.76 - 0.76 0.76 - 0.76
Low: 0.53 - 0.54 0.54 - 0.54
Close: 0.6 - 0.6 0.6 - 0.61

Company Description

SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with other immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with other immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. SQZ Biotechnologies Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.

Headline News

Thu, 23 Mar 2023
Health Care Sector Update for 03/23/2023: SQZ, ETNB, PRTC ... - Nasdaq

Thu, 23 Mar 2023
Sqz Biotechnologies Company Up 27.67% To $0.77 After Earnings Beat - InvestorsObserver

Wed, 22 Mar 2023
Stocks to Watch: Coinbase, Agile Therapeutics, Steelcase, SQZ Biotechnologies - MarketWatch

Wed, 22 Mar 2023
SQZ Biotechnologies Stock Jumps 40% On Confirmed Complete ... - Nasdaq

Wed, 22 Mar 2023
SQZ Biotechnologies Reports Full Year 2022 Financial Results and Recent Portfolio Updates - Yahoo Finance

Wed, 22 Mar 2023
SQZ BIOTECHNOLOGIES CO Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K) -

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NYSE
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 29 (M)
Shares Float 21 (M)
% Held by Insiders 3.1 (%)
% Held by Institutions 66.7 (%)
Shares Short 255 (K)
Shares Short P.Month 264 (K)

Stock Financials

EPS -2.72
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 2.33
Profit Margin (%) 0
Operating Margin (%) -358.7
Return on Assets (ttm) -24.6
Return on Equity (ttm) -77.1
Qtrly Rev. Growth -27.4
Gross Profit (p.s.) -1.47
Sales Per Share 0.74
EBITDA (p.s.) -2.63
Qtrly Earnings Growth 0
Operating Cash Flow -84 (M)
Levered Free Cash Flow -46 (M)

Stock Valuations

PE Ratio -0.23
PEG Ratio -0.1
Price to Book value 0.25
Price to Sales 0.81
Price to Cash Flow -0.22

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.